FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Recovery & cellular-wellness multi-peptide blend
Overview
KLOW is a multi-peptide complex formulated as a synergistic blend studied in recovery, longevity, and cellular-wellness research contexts. Like GLOW, it is supplied as a single co-lyophilised cake so the formulated ratio between components is preserved in the released vial. KLOW is a defined proprietary blend rather than a single molecule, so the released-batch COA characterises it by total peptide content (≥95.0%), peptide-profile mapping by LC-MS, molecular-weight distribution, water, endotoxin, heavy metals, residual solvents, and microbial limits. Exact composition is proprietary and can be disclosed under NDA to qualified B2B accounts.
Applications & buyer fit
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Ratio target, the analytical method to verify it, stability protocol, and packaging are defined in the OEM brief before the first commercial run.
Primary buyer fit: academic and contract research laboratories and regional distributors and re-sellers.
Specifications
Certificate of Analysis
Published released-batch COAs for KLOW Multi-Peptide Complex, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
Browse all published COAsRegulatory note
Proprietary multi-peptide research blend; research-use-only, not for human or veterinary use. Composition is proprietary and disclosed under NDA to qualified accounts.
Frequently asked questions
Both are proprietary co-lyophilised multi-peptide complexes, but they are formulated for different research contexts: GLOW is studied around skin-health and radiance, while KLOW is studied around recovery, longevity, and cellular wellness. Each ships as a single co-lyophilised vial with a released-batch COA verifying total peptide content and peptide-profile mapping. Exact component composition for either blend is proprietary and shared under NDA.
The component peptides and ratios are held as proprietary and are not printed on the public COA. Documented composition disclosure can be arranged under NDA for qualified B2B accounts (distributors, formulators, and labs qualifying a supplier). The public COA still verifies the blend by total peptide content (≥95.0%), LC-MS peptide-profile mapping, and molecular-weight distribution.
Related peptides
